精神病学数位生物标记市场－全球产业规模、份额、趋势、机会及预测（按类型、临床实践、最终用户、地区和竞争格局划分，2021-2031年）

全球精神疾病数位生物标记市场预计将从 2025 年的 7.8698 亿美元大幅成长至 2031 年的 22.6202 亿美元，复合年增长率达 19.24%。

这些生物标记是客观、可量化的生理和行为数据，透过智慧型手机和穿戴式装置等数位平台收集，用于检测和监测精神疾病。其主要成长要素包括：迫切需要客观的临床评估工具来补充患者主观报告的数据，以及在患者照护和药物研发中对可扩展远端监测日益增长的需求。根据数位医学协会2024年预测，在3期临床试验中应用数位化终点，预计每个适应症的净现值（NPV）可提高高达4000万美元，凸显了采用这些创新技术的製药开发商可获得的盈利投资回报（ROI）。

儘管存在这些强劲的商业性驱动因素，但市场仍面临与资料隐私和复杂监管相关的重大障碍。收集高度敏感的心理健康资讯引发了关于患者知情同意、资料安全以及演算法偏见风险的严重伦理问题。这些隐私挑战导致法规环境碎片化，使全球合规变得更加复杂，并有可能削弱患者信任，最终减缓这些数位化解决方案在临床环境中的广泛应用。

市场驱动因素

精神疾病盛行率的不断上升是推动精神疾病数位生物标记应用的重要基础性因素，它将焦点从纯粹的主观报告转向客观、可扩展的诊断工具。随着全球焦虑和忧郁症负担的加重，医疗保健系统越来越依赖数位表型分析来高效管理庞大的患者群体。近期统计数据凸显了这项迫切需求。 2024年7月，美国药物滥用和精神健康服务管理局（SAMHSA）在2023年全国药物使用与健康调查中报告称，约有22.8%的美国成年人在过去一年中患有精神疾病。日益加重的疾病负担迫切需要能够实现持续远端监测的数位工具，以便及早发现行为和生理异常并及时介入。

同时，对数位心理健康技术的投资浪潮正迅速提升这些生物标记的临床有效性和技术水平。新创公司和製药公司正积极投资于精准精神病学平台，利用机器学习进行患者分层和治疗优化。 Alto Neurosciences 就是充分体现市场信心的典型例子，该公司在 2024 年 2 月的首次股票公开发行(IPO) 中筹集了约 1.286 亿美元（请参阅「Alto Neurosciences 公布首次股票公开发行定价」）。这些资金将用于开发基于生物标记的精神疾病治疗方法。消费硬体领域的监管成功推动了这项资金筹措势头。例如，三星电子于 2024 年获得了 FDA 的全新睡眠呼吸中止症检测产品批准，这证实了消费级感测器在神经和精神监测方面的临床应用价值。

市场挑战

资料隐私问题和监管复杂性正对全球精神病学数位生物标记市场施加巨大压力，削弱了临床应用所需的信任。由于这些生物标记依赖于对高度敏感的行为和生理数据的持续追踪，数据管治的模糊性导致医疗服务提供者和患者都产生了强烈的抵触情绪。此外，不同司法管辖区法规结构的碎片化增加了合规成本，延缓了市场准入，有效地阻碍了可扩展远端监测技术的应用。缺乏统一明确的标准引发了人们对演算法偏差和储存安全的担忧，导致相关人员在将这些工具整合到常规临床实践中之前持谨慎态度。

这一障碍的严重程度清晰地体现在医疗专业人员不愿在没有强有力的保障措施的情况下全面采用这些技术。身为患者照护的主要安全隔离网闸，医师们仍然对缺乏严格资料保护保障的工具保持警惕。美国医学会 (AMA) 2024 年的一项调查发现，87% 的医生认为资料隐私保障是采用新型人工智慧医疗解决方案的关键要求。如果没有此类保障，市场将难以将技术能力转化为广泛的临床应用，从而限制治疗覆盖范围和收入成长。

市场趋势

以语音为基础的生物标记正成为诊断领域的一股变革力量，为评估精神疾病的严重程度提供非侵入性、客观的指标。与传统的主观调查不同，这些生物标记利用机器学习来解读音调、音高和节奏等声学细节，从而有可能在焦虑和忧郁症出现临床症状之前，就揭示出与之相关的细微生理变化。这项创新技术正从实验阶段走向实际临床应用，为人群健康管理提供了一个可扩展的方案。 Ellipsis Health 于 2025 年 7 月展示了这项技术的实用性。他们的研究「里程碑式研究检验了语音人工智慧在真实临床实践中检测忧郁症的有效性」表明，一项基于人工智慧的分析对 2007 个病例管理电话进行了分析，其结果与标准 PHQ-8 评估的一致性相关係数达到了 0.54。

同时，分散式精神临床试验（DCT）的蓬勃发展正在革新药物研发，它利用远端监测工具克服了人口统计和地理障碍。分散式框架最大限度地减少了现场访视的需求，显着提高了参与者的多样性，从而能够在更具代表性的患者群体中评估精神治疗效果。这种方法对于将试验结果推广到更广泛的人群至关重要，而这些人群在精神健康研究中往往代表性不足。 FierceBiotech 于 2025 年 1 月证实了该模式的整体性。基于塔夫茨药物研发研究中心的数据，《利用分散式试验提高病患多样性：一项研究》指出，分散式模式将亚裔参与者的比例提高到 20.9%，而传统模式下这一比例为 14.2%。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球精神医学数位生物标记市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 按类型（穿戴式装置、行动应用程式、感测器、其他）
  • 临床实践（用于诊断的精神科数位生物标记、用于监测的精神科数位生物标记、用于预测/预后的精神科数位生物标记、其他）
  • 按最终用户（医疗保健公司、医疗保健提供者、支付方、其他）划分
  • 按地区
  • 按公司（2025 年）
• 市场地图

6. 北美精神病学数位生物标记市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲精神病学数位生物标记市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区精神病学数位生物标记市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲精神病学数位生物标记市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

10. 南美精神病学数位生物标记市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球精神病学数位生物标记市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Koneksa Health Inc
• Biogen, Inc
• Empatica Inc
• VivoSense, Inc
• IXICO plc
• Huma Therapeutics Limited
• Sonde Health, Inc
• Clario

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Psychiatric Digital Biomarkers Market is projected to expand significantly, rising from USD 786.98 Million in 2025 to USD 2262.02 Million by 2031, reflecting a CAGR of 19.24%. These biomarkers involve objective, quantifiable physiological and behavioral data harvested through digital platforms like smartphones and wearable devices, aimed at detecting and monitoring mental health conditions. A primary growth engine is the urgent requirement for objective clinical assessment tools to augment subjective patient reporting, alongside the growing necessity for scalable remote monitoring in both patient care and drug development. According to the Digital Medicine Society in 2024, the inclusion of digital endpoints in Phase 3 clinical trials has been shown to boost expected net present value by up to $40 million per indication, underscoring the lucrative return on investment for pharmaceutical developers embracing these innovations.

Despite these strong commercial drivers, the market encounters substantial obstacles related to data privacy and regulatory intricacies. The gathering of highly sensitive mental health information triggers serious ethical issues concerning patient consent, data security, and the risk of algorithmic bias. These privacy challenges contribute to a disjointed regulatory environment that makes global compliance difficult and threatens to diminish patient trust, ultimately slowing the broad clinical adoption of these digital solutions.

Market Driver

The escalating prevalence of mental health disorders serves as a foundational force propelling the uptake of psychiatric digital biomarkers, shifting the focus from purely subjective reporting to objective, scalable diagnostic measures. As global burdens of anxiety and depression rise, healthcare systems depend increasingly on digital phenotyping to manage extensive patient populations efficiently. This critical need is highlighted by recent statistics; the Substance Abuse and Mental Health Services Administration reported in July 2024, within the '2023 National Survey on Drug Use and Health', that roughly 22.8% of adults in the United States experienced a mental illness in the preceding year. This growing disease burden necessitates digital tools that facilitate continuous remote monitoring to identify behavioral or physiological deviations early for prompt intervention.

Concurrently, a wave of investment in digital mental health technologies is rapidly enhancing the clinical validation and technical sophistication of these biomarkers. Venture firms and pharmaceutical companies are aggressively funding precision psychiatry platforms that utilize machine learning for patient stratification and treatment optimization. A key example of this market confidence appeared when Alto Neuroscience raised approximately $128.6 million in its February 2024 Initial Public Offering, as reported in 'Alto Neuroscience Announces Pricing of Initial Public Offering', to fund biomarker-defined psychiatric treatments. This financial drive is bolstered by regulatory achievements in consumer hardware; for instance, Samsung Electronics received FDA De Novo authorization in 2024 for a sleep apnea detection feature, confirming the clinical applicability of consumer-grade sensors for neurological and psychiatric monitoring.

Market Challenge

Data privacy concerns and regulatory complexities exert significant negative pressure on the Global Psychiatric Digital Biomarkers Market by undermining the essential trust needed for clinical implementation. Since these biomarkers depend on the persistent tracking of deeply sensitive behavioral and physiological data, any ambiguity regarding data governance fosters considerable resistance among providers and patients alike. Fragmented regulatory frameworks across various jurisdictions lead to heightened compliance costs and delayed market access, effectively hindering the rollout of scalable remote monitoring technologies. This absence of unified, clear standards intensifies worries about algorithmic bias and storage security, causing stakeholders to pause before integrating these tools into routine care.

The scale of this impediment is clearly reflected in the hesitation of healthcare professionals to fully adopt these technologies without strong safeguards. Physicians, acting as the principal gatekeepers of patient care, remain cautious of tools that lack rigorous data protection guarantees. According to the American Medical Association in 2024, 87% of physicians cited data privacy assurances as a critical requirement for adopting new AI-enabled healthcare solutions. Without such guarantees, the market faces difficulty in translating its technical capabilities into widespread clinical usage, thereby restricting therapeutic reach and revenue expansion.

Market Trends

Vocal and speech-based biomarkers are emerging as a transformative force in diagnostics, offering non-invasive, objective metrics for assessing mental health severity. Unlike conventional subjective surveys, these biomarkers employ machine learning to interpret acoustic details like tone, pitch, and rhythm, which can unveil subtle physiological shifts linked to anxiety and depression before they become clinically visible. This innovation is transitioning from experimental phases to practical clinical use, providing scalable options for population health management. The operational readiness of this technology was demonstrated in July 2025 by Ellipsis Health; their study, 'Breakthrough study validates voice AI for real-world depression detection in healthcare', showed that AI-driven analysis of 2,007 case management calls achieved a concordance correlation coefficient of 0.54 against standard PHQ-8 assessments.

Simultaneously, the proliferation of Decentralized Psychiatric Clinical Trials (DCTs) is revolutionizing drug development by utilizing remote monitoring tools to surmount demographic and geographic hurdles. By minimizing the need for physical site visits, decentralized frameworks notably improve participant diversity, ensuring psychiatric treatments are evaluated across a more representative patient base. This approach is vital for applying trial findings to broader demographic groups that are frequently underrepresented in mental health studies. The efficacy of this model in promoting inclusivity was confirmed by FierceBiotech in January 2025; reporting on data from the Tufts Center for the Study of Drug Development in 'Using decentralized trials improves patient diversity: study', it was noted that decentralized formats raised Asian participant representation to 20.9%, compared to 14.2% in traditional models.

Key Market Players

• Koneksa Health Inc
• Biogen, Inc
• Empatica Inc
• VivoSense, Inc
• IXICO plc
• Huma Therapeutics Limited
• Sonde Health, Inc
• Clario

Report Scope

In this report, the Global Psychiatric Digital Biomarkers Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Psychiatric Digital Biomarkers Market, By Type

• Wearable
• Mobile based Applications
• Sensors
• Others

Psychiatric Digital Biomarkers Market, By Clinical Practice

• Diagnostic Psychiatric Digital Biomarkers
• Monitoring Psychiatric Digital Biomarkers
• Predictive and Prognostic Psychiatric Digital Biomarkers
• Other

Psychiatric Digital Biomarkers Market, By End User

• Healthcare companies
• Healthcare Providers
• Payers
• Others

Psychiatric Digital Biomarkers Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Psychiatric Digital Biomarkers Market.

Available Customizations:

Global Psychiatric Digital Biomarkers Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Psychiatric Digital Biomarkers Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Wearable, Mobile based Applications, Sensors, Others)
  • 5.2.2. By Clinical Practice (Diagnostic Psychiatric Digital Biomarkers, Monitoring Psychiatric Digital Biomarkers, Predictive and Prognostic Psychiatric Digital Biomarkers, Other)
  • 5.2.3. By End User (Healthcare companies, Healthcare Providers, Payers, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Psychiatric Digital Biomarkers Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Clinical Practice
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Psychiatric Digital Biomarkers Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Clinical Practice
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Psychiatric Digital Biomarkers Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Clinical Practice
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Psychiatric Digital Biomarkers Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Clinical Practice
      • 6.3.3.2.3. By End User

7. Europe Psychiatric Digital Biomarkers Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Clinical Practice
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Psychiatric Digital Biomarkers Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Clinical Practice
      • 7.3.1.2.3. By End User
  • 7.3.2. France Psychiatric Digital Biomarkers Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Clinical Practice
      • 7.3.2.2.3. By End User
  • 7.3.3. United Kingdom Psychiatric Digital Biomarkers Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Clinical Practice
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Psychiatric Digital Biomarkers Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Clinical Practice
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Psychiatric Digital Biomarkers Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Clinical Practice
      • 7.3.5.2.3. By End User

8. Asia Pacific Psychiatric Digital Biomarkers Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Clinical Practice
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Psychiatric Digital Biomarkers Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Clinical Practice
      • 8.3.1.2.3. By End User
  • 8.3.2. India Psychiatric Digital Biomarkers Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Clinical Practice
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan Psychiatric Digital Biomarkers Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Clinical Practice
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Psychiatric Digital Biomarkers Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Clinical Practice
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Psychiatric Digital Biomarkers Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Clinical Practice
      • 8.3.5.2.3. By End User

9. Middle East & Africa Psychiatric Digital Biomarkers Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Clinical Practice
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Psychiatric Digital Biomarkers Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Clinical Practice
      • 9.3.1.2.3. By End User
  • 9.3.2. UAE Psychiatric Digital Biomarkers Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Clinical Practice
      • 9.3.2.2.3. By End User
  • 9.3.3. South Africa Psychiatric Digital Biomarkers Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Clinical Practice
      • 9.3.3.2.3. By End User

10. South America Psychiatric Digital Biomarkers Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Clinical Practice
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Psychiatric Digital Biomarkers Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Clinical Practice
      • 10.3.1.2.3. By End User
  • 10.3.2. Colombia Psychiatric Digital Biomarkers Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Clinical Practice
      • 10.3.2.2.3. By End User
  • 10.3.3. Argentina Psychiatric Digital Biomarkers Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Clinical Practice
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Psychiatric Digital Biomarkers Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Koneksa Health Inc
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Biogen, Inc
• 15.3. Empatica Inc
• 15.4. VivoSense, Inc
• 15.5. IXICO plc
• 15.6. Huma Therapeutics Limited
• 15.7. Sonde Health, Inc
• 15.8. Clario

16. Strategic Recommendations

17. About Us & Disclaimer